Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02626130 · ClinicalTrials.gov registry record · Early Phase 1

Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer

A Early Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Early Phase 1
Development phase
29
Enrollment target
1
Study location

NCT02626130 is a Early Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7 that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02626130, a Early Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Early Phase 1
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

This randomized pilot clinical trial studies the side effects of tremelimumab with or without tissue cryoablation in treating patients with kidney cancer that has spread to other places in the body. Tremelimumab binds to a protein called cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is found on the surface of T cells (a type of white blood cell). Tremelimumab may block CTLA-4 and help the immune system kill cancer cells. Cryoablation is a procedure that uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. It is not yet known whether tremelimumab with or without cryoablation is effective in treating patients with kidney cancer.

Conditions Studied

Clear Cell Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v7 Metastatic Renal Cell Cancer

Interventions

  • OTHER Laboratory Biomarker Analysis
  • PROCEDURE Therapeutic Conventional Surgery
  • PROCEDURE Cryosurgery
  • BIOLOGICAL Tremelimumab

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2016-03-30
Est. Completion 2022-06-20
Phase Early Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02626130

The ClinicalTrials.gov registry entry for NCT02626130 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (86% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02626130 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02626130 about?

NCT02626130 is a clinical study titled "Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer". This randomized pilot clinical trial studies the side effects of tremelimumab with or without tissue cryoablation in treating patients with kidney cancer that has spread to other places in the body. Tremelimumab binds to a protein called cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is...

What is the current status of trial NCT02626130?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 29 participants. The study started on 2016-03-30. Estimated completion is 2022-06-20.

What conditions does trial NCT02626130 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7, Metastatic Renal Cell Cancer.

What interventions are being tested in trial NCT02626130?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Cryosurgery (PROCEDURE), Tremelimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02626130?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02626130 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Clear Cell Renal Cell Carcinoma

All registered trials for this condition

Stage IV Renal Cell Cancer AJCC v7

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.